Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
A phase 1/2 trial of LNS8801 and Pembrolizumab in advanced solid tumours, run by Linnaeus Therapeutics, Inc., active and no longer recruiting.
Overview
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab is a phase 1/2 interventional study registered as NCT04130516 by Linnaeus Therapeutics, Inc., with 200 participants enrolled, started 2019-10-21 and due to reach its primary completion in 2026-06-30. Interventions recorded: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER and Pembrolizumab - anti-PD-1 antibody.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.